Literature DB >> 12458052

Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis.

Yanina Galboiz1, Sarah Shapiro, Nitza Lahat, Ariel Miller.   

Abstract

Recent findings have implicated the activity of matrix metalloproteinases (MMPs) in the pathogenesis of multiple sclerosis (MS), while in vivo interferon (IFN)-beta treatment was demonstrated to suppress MMPs. In the present study, the effects mediated by IFN-gamma and IFN-beta on the mRNA and protein expression of MMP-2, its physiological activator, MT1-MMP and its endogenous inhibitor, TIMP-2, by monocytes were evaluated in vitro. The results point to the significance of IFNs in modulating MMPs/tissue inhibitors of MMPs (TIMPs) expression, and support the possibility that the therapeutic effects of IFN-beta may be, in part, due to induction of a shift from "pro-" to "anti-proteolytic" pattern of MMPs and TIMPs expression.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12458052     DOI： 10.1016/s0165-5728(02)00266-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  8 in total

1.  Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.

Authors:  A C Maretti-Mira; M P de Oliveira-Neto; A M Da-Cruz; M P de Oliveira; N Craft; C Pirmez
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 2.  Myeloid cells - targets of medication in multiple sclerosis.

Authors:  Manoj K Mishra; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2016-08-12       Impact factor: 42.937

3.  Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection.

Authors:  Jennifer L Taylor; Jessica M Hattle; Steven A Dreitz; JoLynn M Troudt; Linda S Izzo; Randall J Basaraba; Ian M Orme; Lynn M Matrisian; Angelo A Izzo
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

4.  PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.

Authors:  Hong-Yi Kuo; Yen-Sung Huang; Chin-Hsiu Tseng; Yi-Chen Chen; Yu-Wei Chang; Hsiu-Ming Shih; Cheng-Wen Wu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Coronavirus-induced demyelination of neural pathways triggers neurogenic bladder overactivity in a mouse model of multiple sclerosis.

Authors:  Matthew T McMillan; Xiao-Qing Pan; Ariana L Smith; Diane K Newman; Susan R Weiss; Michael R Ruggieri; Anna P Malykhina
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-09

Review 6.  Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks.

Authors:  Robert H Goertsches; Michael Hecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

7.  Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells.

Authors:  Ann-Christin Albertsmeyer; Vinodh Kakkassery; Sandra Spurr-Michaud; Olivia Beeks; Ilene K Gipson
Journal:  Exp Eye Res       Date:  2009-12-29       Impact factor: 3.467

8.  High-Plex RNA Expression Profiling of Formalin-Fixed Paraffin-Embedded Synovial Membrane Indicates Potential Mechanism of Mesenchymal Stromal Cells in the Mitigation of Posttraumatic Osteoarthritis.

Authors:  Laura E Keller; Lisa A Fortier; Michelle L Delco; Mana Okudaira; Liliya Becktell; Marta Cercone
Journal:  Cartilage       Date:  2021-02-19       Impact factor: 3.117
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.